The change that matters most. The 2025 GOLD report introduced a phenotype-based exacerbation classification that incorporates blood eosinophil count to guide corticosteroid decision-making. An eosinophil count above 300 cells/µL predicts steroid response. Below 100 suggests poor steroid response and possible bacterial etiology warranting antibiotic prioritization. This is bedside-actionable and changes how you read the CBC on your COPD exacerbation patient.
What changed for NIV in COPD exacerbation. GOLD 2025 strengthened its recommendation for early NIV in acute hypercapnic exacerbations — before PaCO2 reaches crisis levels, not as a rescue after other interventions fail. The evidence for early NIV reducing intubation rates and mortality in COPD exacerbations is now rated high certainty. If your unit uses NIV reactively in COPD, the guidelines are ahead of your protocol.
The triple therapy update. GOLD 2025 reinforces that LAMA/LABA/ICS triple combination reduces exacerbation rates in patients with frequent exacerbations and elevated eosinophils. RT patient education implication: patients on triple maintenance therapy who present in exacerbation should prompt inhaler technique and adherence assessment before assuming the regimen has failed.
Action: Download the GOLD 2025 Pocket Guide at goldcopd.org — free PDF, 30 pages. Know what the eosinophil count is on your current COPD exacerbation patients. It is in the CBC you already have.
The evidence picture. For low-risk extubations — HFNC over conventional oxygen. For high-risk extubations (COPD, OHS, hypercapnia, post-cardiac surgery) — NIV preferred over HFNC alone. For the highest-risk patients — NIV plus HFNC during NIV-off periods is the strongest current strategy.
Why the combination works. Patients need breaks from NIV masks. Standard oxygen during those breaks causes significant desaturation in high-risk patients. HFNC during NIV-off periods maintains positive end-expiratory effect without the mask burden — preventing the desaturation events that cause reintubation.
The one exception. Non-hypercapnic post-extubation failure does not benefit from NIV and may be harmed by it if NIV delays reintubation. HFNC only in that scenario. Knowing which patient is which is the RT clinical judgment that determines which tool goes on.
The rule: High-risk extubation → NIV + HFNC combination. Low-risk → HFNC over conventional O2. Non-hypercapnic post-extubation failure → HFNC, not NIV. Put this in your unit’s extubation checklist.
The problem. Tracheostomy patients are decannulated based on physician comfort and tradition more often than on documented clinical criteria. Some patients stay trached weeks longer than necessary. Others are decannulated prematurely. Neither outcome is acceptable when evidence-based RT-led decannulation criteria exist.
What RT-led decannulation protocols include. Five sequential assessments: (1) secretion burden and self-clear capacity; (2) cuff deflation tolerance — sustained SpO2 and work of breathing without cuff inflation; (3) speaking valve trial — Passy Muir valve tolerance for minimum 30 minutes; (4) capping trial — full tube occlusion for 24 hours with stable gas exchange; (5) SLP swallowing evaluation to clear for decannulation without aspiration risk. RTs can lead assessments 1 through 4 independently in most facility scopes.
The Passy Muir valve specifically. Patients who tolerate PMV for 30 or more minutes with stable work of breathing and no significant desaturation have a high decannulation success rate. Patients who fail PMV trials within that window need reassessment before progressing. This is RT-owned clinical data that directly informs the decannulation decision.
If your unit does not have an RT-led decannulation protocol: Propose one. The AARC has published clinical practice guidelines on tracheostomy care. This is scope expansion that is evidence-backed and administratively accessible — no state legislation required.
The question. How many of your current staff RTs are within five years of retirement — and what is your department’s specific plan for that transition? One third of the current RT workforce is over 50. Departments that have not mapped their succession gap will face it as an emergency.
The supply math. BLS projects 8,600 RT job openings annually through 2032. Total RT program graduates nationally: approximately 6,500 per year. The gap is not closing. Departments relying on the open market to fill senior positions will consistently lose to facilities building their own pipelines.
Three things that move the needle. First: identify your top two or three mid-career RTs and have a direct conversation about leadership interest. People who are not asked do not pursue. Second: build a formal clinical ladder so expertise stays in your department rather than walking out to travel. Third: contact the nearest RT program about a preceptorship pipeline. Facilities that provide excellent clinical training are the ones new graduates apply to first.
If you are a staff RT reading this: The leadership gap is your opportunity. Departments are actively looking for experienced RTs who want to move into charge and leadership roles. If you have considered it — this is the market to make the move.
Next: Neonatal transport RT — the most demanding subspecialty in respiratory therapy, credentials required, and what the career actually looks like.
Soon: Home mechanical ventilation in 2026 — the growing patient population most hospital RTs are underprepared to discharge safely.
On deck: AARC Congress 2026 New Orleans preview — what is on the agenda and why you should be there in November.
Staying at the vent,
15 years across academic medical centers & community hospitals
